Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (2009 - 2026)
Gilead Sciences (GILD) reported EPS (Weighted Average and Diluted) of $1.61 for Q1 2026, up 54.81% on a YoY basis from $1.04 in Q1 2025, and down 7.47% quarter-over-quarter from $1.74 in Q4 2025.
Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (2009 - 2026) Analysis & Trends
Gilead Sciences has reported EPS (Weighted Average and Diluted) for 18 years, with the latest figure at $1.61 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 54.81% year-over-year to $1.61; the trailing twelve-month figure through Mar 2026 stood at $7.34 (up 54.53% YoY), and the FY2025 full-year result was $6.78, up 1684.21% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.61, down from $1.74 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $2.43 in Q3 2025, with the low at -$3.34 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.99 across 5 years, with a median of $1.29 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) soared 3900.0% — and 2024, when it sank 517.5%.
- Gilead Sciences' EPS (Weighted Average and Diluted) stood at $1.3 in 2022, then retreated by 13.08% to $1.13 in 2023, then increased by 25.66% to $1.42 in 2024, then increased by 22.54% to $1.74 in 2025, then retreated by 7.47% to $1.61 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $1.61 (Q1 2026), $1.74 (Q4 2025), and $2.43 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.31 |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 |
| Dec 31, 2025 | 1.74 |
| Sep 30, 2025 | 2.43 |
| Jun 30, 2025 | 1.56 |
| Mar 31, 2025 | 1.04 |
| Dec 31, 2024 | 1.42 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | 1.29 |
| Mar 31, 2024 | -3.34 |
| Dec 31, 2023 | 1.13 |
| Sep 30, 2023 | 1.73 |
| Jun 30, 2023 | 0.83 |
| Mar 31, 2023 | 0.80 |
| Dec 31, 2022 | 1.30 |
| Sep 30, 2022 | 1.42 |
| Jun 30, 2022 | 0.91 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2021 | 0.30 |
| Sep 30, 2021 | 2.05 |
| Jun 30, 2021 | 1.21 |